Biomarin Pharmaceutical reported $410.67M in Gross Profit on Sales for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US $ 131.9M 19.38M
Acorda Therapeutics ACOR:US $ 22.25M 5.68M
Agios Pharmaceuticals AGIO:US $ 5.15M 4.65M
Alnylam Pharmaceuticals ALNY:US $ 184.01M 6.38M
Amgen AMGN:US $ 5084M 407M
Bayer BAYN:GR 7.14B 2.32B
Biogen BIIB:US $ 2105.1M 327.2M
Biomarin Pharmaceutical BMRN:US $ 410.67M 8.28M
Bluebird Bio BLUE:US $ -226000 6.14M
Gilead Sciences GILD:US $ 4818M 348M
Insmed INSM:US $ 48.83M 7.91M
Intercept Pharmaceuticals ICPT:US $ 71.45M 16.38M
IONIS PHARMACEUT IONS:US $ 129.05M 8.7M
Moderna Inc MRNA:US 3.37B 1.68B
Neurocrine Biosciences NBIX:US $ 373.4M 67.4M
Ptc Therapeutics PTCT:US $ 155.89M 17.29M
Puma Biotechnology PBYI:US $ 44.6M 9.71M
Regeneron Pharmaceuticals REGN:US $ 2560.1M 0.1M
Sarepta Therapeutics SRPT:US $ 195.69M 16.3M
Seattle Genetics SGEN:US $ 391.4M 52.57M
Ultragenyx Pharmaceutical RARE:US $ 81.07M 7.24M
United Therapeutics UTHR:US $ 437.2M 1.2M
Vertex Pharmaceuticals VRTX:US $ 1934.4M 82.7M
YTE INCY:US $ 866.16M 170.14M